Login / Signup

Comparative genomic analysis of PIK3R1-mutated and wild-type breast cancers.

Melody A CobleighKayla Viets LayngElizabeth MauerBrett MahonAdam J HockenberryAbde M Abukhdeir
Published in: Breast cancer research and treatment (2023)
This is the largest investigation of the PIK3R1 mutational landscape in breast cancer patients (n = 6,009). PIK3R1 mutations were more common in triple-negative breast cancer (~ 6%) than in HER2 + or HER2-/HR + disease (approximately 2%). While alterations in the PI3K/AKT pathway are often actionable in HER2-/HR + breast cancer, our study suggests that PIK3R1 could be an important target in TNBC as well.
Keyphrases
  • wild type
  • single cell
  • breast cancer risk